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Introduction
Viscerotropic strains of Leishmania donovani and Leishmania 
infantum, causing visceral leishmaniasis (VL), are responsible for 
a significant health burden worldwide, with 200,000 to 400,000 
new cases reported annually and ~20,000–40,000 deaths1. One 
of the principal drugs used in the treatment of VL is ampho-
tericin B, a repurposed anti-fungal agent which has been used 
to treat VL in multiple formulations, including both free drug, 
and various liposomal formulations2,3. AmBisome®, a formula-
tion based on incorporation of amphotericin B into liposomes, 
is currently the first line therapy for VL in South Asia3 pro-
vided by the manufacturer Gilead initially at reduced cost and 
subsequently as a donation4. The introduction of AmBisome® 
monotherapy has contributed significantly to the current 
elimination effort for VL in South Asia, but its efficacy in 
East Africa, alone or in combination with other drugs has been 
disappointing5. Recent studies suggest that the efficacy of 
AmBisome® monotherapy in HIV-VL patients can be improved 
by combination with miltefosine, extending its utility for this 
indication in East Africa6. AmBisome® has also been used for 
cutaneous leishmaniasis (reviewed in 7).
Amphotericin B is a macrocyclic, polyene antibiotic produced 
by Streptomyces nodosus and it is known to act via irreversibly 
binding to ergosterol in the cell membrane, causing disrup-
tion of membrane integrity and cell death8,9. Off target toxic-
ity is likely due to binding of cholesterol in mammalian cell 
membranes and this is minimized by sequestration of ampho-
tericin B within liposomes, such as in AmBisome®10. Delivery 
into cells via liposomes may allow amphotericin to display 
additional cidal properties including generation of reactive 
oxygen species, possibly mediated through binding to ergosterol 
in the membranes of intracellular vesicles or mitochondria11. 
The immune properties of amphotericin B and its liposomal 
formulations have been extensively described elsewhere11,12. 
For example, free amphotericin B and to a lesser extent liposomal 
amphotericin B were shown to inhibit T and B cell proliferation 
in vitro13, and in vitro and in vivo CD8+ T cell-mediated 
cytotoxicity14. Both free and liposomal amphotericin B also 
induce myeloid cell inflammatory cytokine production15,16, 
likely via interaction with TLR2 and CD1417 and this probably 
underlies many of the immunomodulatory properties observed 
in different models of fungal immunity11. Less work has been 
done to unravel the immunomodulatory role of amphotericin 
B in the context of leishmaniasis. For example, in humans 
treated with another liposomal formulation Fungisome®, 
cytokine responses elicited from re-stimulated PBMC one week 
after single dose treatment were indicative of cure and poten-
tial for relapse18. A further study reported altered levels of 
anti-inflammatory cytokines in BALB/c mice infected with 
L. donovani and treated with Kalsome10, another liposomal 
formulation19. A comprehensive analysis of host response changes 
following AmBisome® treatment using whole blood transcrip-
tomic analysis20 as well as a detailed investigations of CD8+ and 
CD4+. T cell phenotypes pre and post treatment have recently been 
reported from studies of VL patients in Bihar21,22. However, studies 
on systemic responses pre and post treatment are rare and more 
limited in scope, given the ethical challenges of such work in 
humans. For example, TLR2 and TLR4 mRNA accumulation 
was reported to be elevated in pre-treatment splenic 
aspirates compared to those taken 3–4 weeks after treatment23, 
as were mRNAs for IL-27p28, EBI-3 and IL-2124. We have 
found no reports on changes in the hepatic immune response to 
L. donovani infection in humans.
The spleen and liver are major targets of human infection and at 
least in rodents, show differential immune and immunopatho-
logical responses to L. donovani infection25–27. Furthermore, 
hepatic and splenic dysfunction account for some of the more 
serious pathologies associated with VL, including splenom-
egaly, anaemia, thrombocytopenia, as well clinical characteristics 
of hepatitis and cirrhosis. Of note, spleen size at discharge was 
found to be a major risk factor for relapse after AmBisome® 
treatment in India28 and after sodium stibogluconate (SSG) or 
SSG/ paromomycin (PM) treatment in southern Sudan29. In 
an initial report30, we used transcriptomic profiling to define 
changes in spleen, liver and blood transcriptome over the course 
of 42 days of infection in the BALB/c mouse model of VL. 
Here, we extend this analysis to ask the following questions: 
i) what are the systemic transcriptional changes that accom-
pany AmBisome® treatment in this model? and ii) to what extent 
does the spleen and liver transcriptome return to a homeostatic 
state following parasitological cure? In addition, we define the 
extent to which AmBisome® treatment affects host transcrip-
tome in the absence of microbicidal activity, using a model of 
M. bovis BCG infection. The results reported here indicate that 
drug treatment leads to a rapid resolution of granulomatous inflam-
mation in the liver which is reflected by whole scale changes in 
transcriptome associated with loss of immune cells. In 
contrast, splenomegaly remains after parasitological cure and 
the transcriptome reflects ongoing processes of tissue remod-
elling and enhanced stem and hematopoietic activity. Direct 
effects of AmBisome® are related to low grade myeloid cell 
activation. These data provide novel insights into disease 
resolution after chemotherapy and also highlight potential 
targets for improving or accelerating a return to homeostasis.
Methods
Ethics statement
Experiments were approved by the Animal Welfare and Eth-
ics Review Bodies of the University of York and the LSHTM 
and the work was performed under UK Home Office license 
(PPL 60/4377; PPL 70/6997; PPL 70/8207). Mice were killed 
by exsanguination under terminal anaesthesia prior to tissue 
collection, as described below.
Mice and infections
Female BALB/c mice (Charles River, Margate, UK) weighing 
20±1 gm and health screened to FELASA 67M standard and 
maintained under specific pathogen free conditions in indi-
vidually ventilated cages were used in this study. Leishmania 
donovani (LV9; WHO Ref name: MHOM/ET/67/HU3)) parasites 
were maintained in B6. Rag1-/- mice and amastigotes prepared 
following tissue disruption and differential centrifugation, as 
described elsewhere31. 2×107 amastigotes in 150 µl RPMI were 
injected intravenously (i.v.) via the lateral tail vein and 
without anaesthetic to initiate infection. After infection, mice 
were allocated to cages of 5 and provided food and water 
·½»ʺÅ¼ʹʸ
»ÂÂ¹ÅÃ»Æ»Ä»É»·È¹¾ʹʷʸˀƑʻƓʸˀʿ·ÉÊËÆº·Ê»ºƓʷʺ	ʹʷʹʷ
adlibitum. The naïve and d36 and d42 untreated infected mice 
reported here (n=5 per group) were part of the previously 
described CRACK-IT_2 cohort30. An additional 10 mice were 
infected at the same time and following randomisation along 
with the other groups, treated at d35 with 8mg/kg AmBisome® 
i.v. Five mice from this cohort were killed at day 36 (R
x
+1) and 
day 42 (R
x
+7) and compared to their time matched counter-
parts. All animals were killed and processed over an approxi-
mate time period of 4–6h beginning in the morning. Tissues 
were aseptically removed post mortem and stored/processed as 
detailed below. Parasite loads were determined using the 
impression smear technique and are reported as Leishman 
Donovan Units32. All downstream tissue analysis was per-
formed blinded to group by investigators not involved in animal 
handling. For infection with M. bovis BCG, ten additional 
female BALB/c mice were infected i.v. with 2x106 CFU / mouse 
of the BCG-SSI (Aeras stock Lot No. 050613MF) and at 35d 
post infection, five were treated with AmBisome® as above and 
five remained untreated. All BCG-infected mice were killed at 
d42 (R
x
+7) and tissue homogenates were plated for 22 days. 
Mycobacterial counts are expressed as log CFU/organ.
Tissue transcriptomics
Transcriptomic analysis of RNA using Agilent SurePrint G3 
mouse GE 8x60 microarray chips isolated from tissues of 
Leishmania infected mice were processed and analysed as 
described in 30. Tissue from mice infected with M. bovis BCG, 
were processed for transcriptomic analysis by RNA-Seq. Paired 
end illumina RNA sequencing libraries were generated using 
polyA enrichment followed by using the NEB next RNA kit as 
per manufacturer’s instructions. Libraries were sequenced 
by Illumina HiSeq 2500, using 2 x 100bp reads. Universal 
illumina adaptors were removed using cutadapt v 1.8.3. Unpaired 
reads were removed, and reads were further trimmed and 
scored for quality using sickle v 1.33 (https://codeload.github.com/ 
najoshi/sickle/tar.gz/v1.33). Reads were then aligned using 
STAR aligner v 2.5.1b using the sjdbOverhang 150 to Mus 
Musculus version 89 from ENSEMBL33,34. Non uniquely reads 
were filtered out and gene expression was calculated using 
the union algorithm in HTseq-count. DE expressed genes 
were identified through the R package edgeR34. The data was 
normalised using this package, and pairwise comparisons 
were performed using a generalised linear model and using 
Bonferonni multiple testing threshold of 0.05. Unexpressed and 
lowly expressed transcripts were removed using the logged 
counts per million values of expression, and by removing those 
in the bottom 20 percentile. The prcomp function in R was 
used to generate eigenvalues. The first two principal compo-
nents were used to look at groupwise variation, which accounted 
for >80% of the variation between the groups. Volcano plots 
were generated to look at pairwise DE, using log2FC that were 
calculated from the mean values of each group in the pair-
wise comparison. EnrichR was also used to perform additional 
enrichment analysis35,36 and DE genes were assigned into 
KEGG groups using the R package37. Adjusted p values are 
shown in text.
Quantitative morphometry
Digital whole slide images of infected livers were prepared 
from F4/80 and DAPI stained cryosections using an AxioScan 
Z1 slide scanner (Zeiss, Jena, Germany) and analysed using a 
bespoke macro developed within the Strataquest image analysis 
software package (TissueGnostics, Vienna, Austria) as described 
previously30. Data are shown for the number of granulomas 
per mm2 and the size of individual granulomas.
Results
Transcriptomic response to treatment of L. donovani 
infection with AmBisome® 
To study the impact of AmBisome® treatment on host tran-
scriptional profile, we infected BALB/c mice for 36 days, a 
time point when pronounced splenomegaly and a stable splenic 
parasite burden is established. At this time, hepatic resistance to 
infection is already coming into play, with the development of a 
florid granulomatous response, whereas the spleen is undergo-
ing extensive remodelling due to chronic inflammation. These 
histopathological changes are accompanied by significant 
changes to the host transcriptome30. On day one following 
single dose administration of AmBisome® (R
x
+1) there was 
no significant effect on splenic parasite burden (Figure 1A) 
or spleen weight (786 ± 22 vs. 822 ± 50 mg for untreated and 
AmBisome® treated mice, respectively). By seven days post 
treatment (R
x
+7), complete clearance of parasite load to 
below detection limits of the impression smear technique had 
occurred (Figure 1A) and spleen weight was reduced by approxi-
mately 33% (784 ± 35 vs. 526 ± 50; p<0.01). In the liver, how-
ever, AmBisome® had a more rapid leishmanicidal effect, 
reducing parasite load by ~80% at R
x
+1 and again leading to 
complete clearance by R
x
+7 (Figure 1B). Hepatomegaly was not 
significantly different at R
x
+1 (1592 ± 58 vs. 1632 ± 26 mg) 
whereas by R
x
+7, there was a decrease in liver size of approx-
imately 16% (1606 ± 65 vs. 1348 ± 56 mg; p<0.05). Hence, as 
previously shown, AmBisome® is highly effective in treating 
experimental VL in BALB/c mice38.
To evaluate how this pattern of cure was reflected in host 
response, we studied spleen and liver tissue transcriptomes at 
R
x
+1 and R
x
+7, making comparisons against untreated mice 
at each time point, to reduce possible false positives due to any 
changes in transcriptomic response due to the natural progres-
sion of infection. Expression data are shown as volcano plots of 
log2FC against p value for AmBisome® treated vs. untreated mice 
for spleen (Figure 1C) and liver (Figure 1D) at both R
x
+1 and 
R
x
+7. Differentially expressed (DE) genes passing the cut-off 
threshold of FDR<0.05 and log2FCq1 are shown in red. The 
distribution of genes passing this threshold in spleen and liver at 
each time are also indicated by venn diagrams (Figure 1E and F).
At day R
x
+1 in the spleen, only 46 genes (5 UP and 41 
DOWN) were DE between AmBisome®-treated and untreated 
mice at day R
x
+1 (Figure 1C and E), compared to 88 DE 
genes (39 UP and 49 DOWN) in the liver (Figure 1D and F; 
Extended data: Table S1), with no overlap between gene lists 
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Figure 1. Transcriptional changes associated with AmBisome® treatment in L. donovani-infected BALB/c mice. Cohorts of weight 
matched female BALB/c mice were infected with ~2×107 L. donovani amastigotes and at day 35 randomised to receive AmBisome (8mg/kg) 
or saline (untreated). A and B. Parasite loads were determined in spleen (A) and liver (B) at day 36 (R
x
+1) and day 42 (R
x
+7). Data are shown 
as mean Leishman Donovan Units ± SEM (n=5 per group), with p values as indicated. C and D. Differentially expressed genes in spleen (C) 
and liver (D) are presented using a volcano plot, with red symbols indicating genes passing the FDR<0.05 and log2FC=1 cut off. Genes with 
positive DE are UP in AmBisome®-treated vs. untreated mice and vice versa. E and F. Venn diagrams to indicate the number of up and down 
regulated genes and their overlap in spleen (E) and liver (F), comparing AmBisome®-treated vs. untreated mice.
in the two tissues. Using the protein-protein interaction data-
base STRING39, the products of down regulated genes in the 
spleen showed no specific enrichment. In the liver, up-regulated 
genes were enriched for GO terms “metallopeptidase activ-
ity” (FDR 0.0156), “cellular response to interleukin 1” (FDR 
0.0225), collagen catabolic process and cellular response to 
tumour necrosis factor (both FDR 0.0258). Down-regulated 
hepatic genes were enriched for KEGG pathways linoleic 
acid metabolism (FDR 0.0111), bile secretion (FDR 0.0167), 
and steroid hormone biosynthesis and retinol metabolism 
(all FDR 0.0173).
At R
x
+7, 113 genes were DE in spleen (58 UP and 55 DOWN; 
Figure 1E; Extended data: Table S1). No specific enrichments 
were found using STRING within the upregulated gene list, 
whereas down regulated genes were significantly enriched for 
GO terms “response to molecule of bacterial origin”, “defence 
response”, “inflammatory response” and “cellular response to 
IL-1” (all FDR 5.62x10-4). Enriched KEGG pathways included 
“TNF signalling” (FDR 4.37x10-5), “Salmonella infection” 
(FDR 0.00407), “Chagas disease” (FDR 0.0078) and “Leishma-
niasis” (FDR 0.0205). Immune-related molecules down regu-
lated in expression in the spleen at R
x
+7 included Ccl2, Cxcl2, 
Irg1, Il6, IL23r, Msr1, Nos2, Ptgs2, Saa1, Saa3, Timp1 and 
Ms4a6d. Surprisingly, no other cytokines, TNF family members 
or molecules with CD designations were affected by AmBisome® 
treatment in the spleen, despite parasite clearance.
In liver, 400 genes were DE by R
x
+7 (319 DOWN, 81 UP; 
Figure 1F; Extended data: Table S1). Similar to spleen, 
down-regulated genes were significantly enriched for GO terms 
including “defense response”(FDR 2.77x10-39) and immune 
system process” (FDR 1.37x10-36) and KEGG pathways 
“cytokine-cytokine receptor interaction” (FDR 1.15x10-14) and 
“leishmaniasis” (FDR 1.55x10-13) forming a major cluster of 
interaction defined using STRING (Extended data: Figure S1). 
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Genes clearly associated with immune function (e.g. CD designa-
tion, cytokines/chemokines, lectin-like receptors etc) accounted 
for 23% (74/319) of these down-regulated genes and featured a 
number of genes associated with pathogen recognition, macro-
phage activation and T cell regulation, including the cytokines 
Tnf and Ifng, and the checkpoint regulators Lag3, Cd274 (PD-L1) 
and Pdcd1lg2 (PD-L2) (Figure 2). In addition, a large cluster 
of genes associated with cell cycle regulation was also down 
regulated (Extended data: Figure S1). In contrast, up-regulated 
genes were enriched for GO terms related to fatty acid metabolic 
processes” (FDR 5.03x10-5), monocarboxylic acid metabolic 
process (FDR 1.0x10-4), “lipid metabolic processes” (FDR 
1.17x10-4) and KEGG pathways “fatty acid elongation”, 
“biosynthesis of unsaturated fatty acids” and insulin signalling 
pathway (all FDR 0.0109) (Extended data: Figure S2).
Only a small subset of DE genes was co-regulated in both 
spleen and liver at R
x
+7 (6 UP and 24 DOWN; Extended data: 
Table S1). Commonly upregulated genes were Ccrl1/Ackr4 
(atypical chemokine receptor 4), Epx (eosinophil peroxidase), 
Prg2 (proteoglycan 2 / mMBP-1), Prg3 (proteoglycan 3 / MBP2), 
Ear7 (eosinophil-associated, ribonuclease A family, 
member 7) and Ear6 (eosinophil-associated, ribonuclease 
A family, member 6), suggesting a heightened eosinophilic 
response in both tissues after treatment with AmBisome®. 
Within the common downregulated gene list, there was enrich-
ment for GO terms related to host defence and inflammation 
(GO:0009617, FDR 6.70x10-6; GO:0006954, FDR 1.33x10-5; 
GO:0006952, FDR 3.39x10-5) and this list also included markers 
related to macrophage activation including Pdcd1lg2 
(PD-L2), Irg1, Fos, Marco, Nos2, Ptgs2, Ccl2, Clec4e, 
Ms4a6d, and Il6. 
Collectively, these data indicate that although both spleen and 
liver ultimately clear their parasite burden by R
x
+7, they do 
so with differing kinetics and with tissue-specific changes in 
host transcriptional profile.
Analysis of immune pathways affected by AmBisome® 
treatment
In order to gain a deeper appreciation of immune-related 
changes associated with AmBisome® treatment, gene set enrich-
ment analysis was performed. For each DE gene list generated 
in spleen and liver at both R
x
+1 and R
x
+7, we conducted path-
way enrichment against the MSigDB Hallmark gene set 
panel and the Immunology C7 panel. Full outputs from the 
analysis are included in the Extended data (Table S2). The 
top ten most significant enrichments (above a threshold of 
FDR 0.05) are shown for each time point and each direction 
(Figure 3). Genes downregulated in AmBisome® treated mice 
at R
x
+7, most prominently within the liver, were significantly 
enriched in MSigDB gene sets associated with lymphocyte 
and myeloid cell responses, notably those relating to T cell 
activation and IFNG and TNF responses signalling. Collectively, 
these data suggest that by R
x
+7, there has been a significant 
reduction in T cell and myeloid cell content and/or function 
in both spleen and liver.
Reduction in granulomatous inflammation is largely 
responsible for observed changes in hepatic transcriptome 
following AmBisome® treatment
To determine whether the changes in hepatic transcrip-
tome associated with AmBisome® treatment were a result of 
changes in gene expression or in the cellular composition of 
the tissue, we analysed tissue sections to describe the extent 
Figure 2. Immune genes down regulated following AmBisome® treatment in the liver. 74 immune-associated down regulated genes 
grouped according to functional category or main cellular localisation. Log2 fold change in expression is indicated. IRGs, interferon regulated 
genes, PPRs, pattern recognition receptors. Full list of up and down regulated genes at each time post treatment are found in Extended data: 
Table S1.
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of granulomatous inflammation, a hallmark of the hepatic 
response to L. donovani26. We used quantitative image analysis 
based on granulomas defined by a F4/80+ core and surrounded by 
a cellular infiltrate (see Methods; Figure 4). At R
x
+1, we observed 
no significant change in granuloma number or granuloma size 
compared to non-drug treated mice (Figure 4A and B). 
Although granuloma numbers were already declining in infected 
untreated mice (compare Figure 4A and C), commensurate 
with the known kinetics of the hepatic response32, AmBisome® 
treatment rapidly accelerated granuloma clearance from the 
liver, with a >99% reduction in granuloma number per unit area 
(6.23±1.53 vs. 0.098±0.07/mm2, in AmBisome® treated vs. 
untreated mice respectively; Figure 4C) at R
x
+7. Of interest, 
the few remaining granulomas were also significantly smaller 
in size (Figure 4D). Taken together, it appears that the changes 
in transcriptomic profile associated with AmBisome® treatment 
at the tissue level reflect changes in cellularity and a cessation 
of granulomatous inflammation following parasite clearance, 
rather than changes in cellular gene expression per se.
AmBisome® has subtle direct effects on the host 
transcriptome masked by its anti-leishmanial properties
Anti-leishmanial drugs, including AmBisome®, have been 
ascribed immunomodulatory properties11, though limited stud-
ies have addressed this question in vivo. We therefore asked 
whether the clear changes in inflammatory response associ-
ated with the leishmanicidal activity of AmBisome® might 
obscure any direct effects of the drug on host cellular function. 
Figure 3. GSEA analysis of DE genes in spleen and liver after AmBisome® treatment. Figure shows pathway enrichment for DE genes 
identified in Extended data: Table S1, according to gene set and number of genes. Full descriptions of gene sets and analysis are provided 
in Extended data: Table S2. 
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In order to remove this confounder, we made use of the observa-
tion that M. bovis BCG also induces hepatic granulomas40, yet this 
organism has not been reported to be sensitive to amphotericin 
B. We infected a cohort of BALB/c mice with M. bovis BCG and 
at d35 post infection, mice were either treated with AmBisome® 
or remained untreated. CFU counts from liver at R
x
+7 con-
firmed that M. bovis BCG was insensitive to AmBisome® 
(Figure 5A). There was also no reduction in hepatomegaly 
(1412 ± 98 vs. 1580 ± 183 mg in untreated and treated mice, 
respectively; Figure 5B). Furthermore, histological analysis 
indicated that AmBisome® treatment did not affect granuloma 
number or cellularity in M. bovis BCG infected mice 
(Figure 5C and Figure 5D). Transcriptomic profiling was per-
formed, and DE genes identified by comparison of untreated and 
AmBisome®-treated M.bovis BCG infected mice at R
x
+7. 
Only 3 genes passed a threshold of logCPM >1 and log2FC 
> 1 in the liver of M.bovis BCG-treated mice at R
x
+7 (UP: 
Lcn2, Mmp12, and Orm2). To explore whether more sub-
tle effects could be detected, we removed the threshold and 
examined all genes where there was statistical significance of 
P<0.05. 295 genes (208 UP and 87 DOWN) were scored as DE 
on this criteria and pathway analysis identified a high degree of 
enrichment for genes associated with macrophage activation 
(Table 1; Extended data: Table S3). Importantly, genes associ-
ated with phagocytes and innate recognition that were identified 
as down regulated in L. donovani-infected treated mice were 
found to be upregulated in similarly treated M.bovis BCG-
treated mice, including Tlr2, Sirpa, Nos2, Ms4a6d, Lyz2, Irf8 
and H2-Aa. This pattern of a low-level change in expression of 
myeloid-associated genes was also evident more broadly, with 
high representation within gene sets identified in relation to 
myeloid function in a range of diseases (FDR values of 2.96 x10-10 
to 5.33x10-13; Extended data: Figure S3). In contrast, genes 
associated with lymphocyte function and related cytokine and 
chemokine genes whose mRNAs were reduced in abundance 
after treatment of L. donovani infected mice (Figure 2), were 
unaltered in treated M. bovis BCG-infected mice (Extended 
data: Table S2). Collectively, these data suggest AmBisome® 
treatment stimulates low grade activation of myeloid cell 
function, but that this may be masked due to the much more 
significant negative effects associated with loss of inflammatory 
stimulus resulting from the elimination of Leishmania amas-
tigotes. Hence, the main impact of AmBisome® on the liver 
transcriptome in L. donovani-infected mice as seen here likely 
represents an indirect consequence of its leishmanicidal activity 
and reduction in parasite load.
Parasitological clearance does not restore immune 
homeostasis
Although AmBisome® is highly effective in clearing para-
sites in animal models and in humans, the extent to which 
the immune response and other parameters return to home-
ostasis early after treatment in systemic tissues is unknown. 
Splenomegaly was clearly still evident at the end of treat-
ment (526 ± 50 vs. 94 ± 7 mg for AmBisome®-treated mice at 
R
x
+7 and naïve control mice, respectively; p<0.0001), as was 
hepatomegaly (1348 ± 56 mg vs. 968 ± 49 mg; p<0.001). We 
Figure 4. Granulomatous inflammation in L. donovani-infected BALB/c mice treated with AmBisome®. The hepatic granulomatous 
response was evaluated using quantitative morphometrics on F4/80-stained cryosections, as Methods. A and B. Response to treatment at 
R
x
+1. C and D. Response to treatment at R
x
+7. Data are presented as number of granulomas per unit area (A and C) and average granuloma 
size (B and D). Data are derived from whole mount analysis of a single section per mouse and n=4 or 5 mice per group, with p values as 
indicated determined by unpaired t test. 
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Figure 5. AmBisome® treatment of M. bovis BCG-infected BALB/c mice does not impact on hepatic mycobacterial load, hepatomegaly 
or granulomatous inflammation. Female BALB/c mice were infected with ~2×106 M. bovis BCG (BCG-SSI, Aeras) and at d35 post infection 
treated or not with 8mg/kg AmBisome®. At R
x
+7, mice were killed, livers weighed, and liver tissue plated to assess growth of viable mycobacteria 
and processed for histology. A. hepatic mycobacterial tissue load. B. Hepatomegaly. C and D. Granulomatous inflammation was quantified 
by number of granulomas per unit area (C) and average granuloma size (D). Data are presented for individual mice and the mean is shown 
(bar); p=ns for CFU/organ and liver weight (n=5 per group), and for measures of granulomatous inflammation (n=4 per group).
therefore compared the transcriptomic profile of untreated 
and drug-treated infected mice at both R
x
+1 and R
x
+7 with 
that of age/sex-matched control mice using principal com-
ponent analysis (PCA), a statistical technique to reduce data 
dimensionality and identify patterns in data. Only the first 
two principal components were used to calculate the similar-
ity between groups, as this represented 77.5% and 80.7% of the 
total variation in the spleen and liver, respectively. The direc-
tionality of these is shown as a biplot in Figure 6. In both 
spleen (Figure 6A) and liver (Figure 6B), control naive mice 
clustered most tightly indicative of a low level of intra-group 
variability, with the main source of variation along the x axis. 
Not unsurprisingly, untreated infected mice were most dis-
similar to naïve mice and also clustered together. In keep-
ing with the number of DE genes and the kinetics of parasite 
clearance, untreated and R
x
+1 were more closely aligned 
than samples from each tissue at R
x
+7. For liver samples, the 
untreated control mice at day 42 also showed a shift in posi-
tion compared to d36 untreated mice, indicative of the onset 
of natural immunity in the liver but not spleen of L. donovani- 
infected mice (Figure 1). More importantly, R
x
+ 7 sam-
ples shifted away from untreated mice and in the direction of 
naïve mice. However, it was clear that such samples took an 
intermediate position relative to naïve and untreated infected 
mice. Based on this criterion, restoration to homeostasis 
appeared more complete in liver compared to spleen.
Genes not reverting to baseline expression after 
AmBisome® induced parasite clearance
In the liver, 3733 genes (2107 UP; 1626 DOWN) were DE 
between AmBisome®-treated and naïve mice at R
x
+1 reducing 
to 1518 genes (1294 UP; 224 DOWN) at R
x
+7. In the spleen, 
2035 genes (881 UP: 1154 DOWN) were DE between treated 
and naïve mice at R
x
+1 reducing to 1196 genes (481 UP; 715 
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Table 1. Gene set enrichment analysis of DE genes after AmBisome® treatment of M. bovis BCG-
infected BALB/c mice.
Mouse Gene Atlas
Term Overlap P-value Adjusted 
P-value
Odds 
ratio
Combined Score
liver 52/928 2.37E-17 2.28E-15 3.891 148.96
macrophage_peri_LPS_thio_0hrs 28/353 2.72E-13 1.31E-11 5.508 159.37
macrophage_peri_LPS_thio_1hrs 35/598 1.93E-12 6.18E-11 4.064 109.63
macrophage_peri_LPS_thio_7hrs 33/707 3.00E-09 7.19E-08 3.241 63.61
macrophage_bone_marrow_24h_LPS 23/551 5.47E-06 1.05E-04 2.899 35.12
macrophage_bone_marrow_6hr_LPS 26/730 2.20E-05 3.52E-04 2.473 26.53
dendritic_cells_lymphoid_CD8a+ 9/142 2.21E-04 0.0030295 4.401 37.05
spleen 6/100 0.0032574 0.0390883 4.167 23.86
macrophage_bone_marrow_0hr 8/180 0.0046569 0.0496739 3.086 16.57
KEGG 2019 Mouse
Term Overlap P-value Adjusted 
P-value
Odds 
Ratio
Combined Score
Leishmaniasis 11/67 2.87E-09 8.69E-07 11.401 224.26
Tuberculosis 16/178 6.75E-09 1.02E-06 6.2422 117.44
Phagosome 15/180 5.57E-08 5.62E-06 5.7870 96.66
Glycine, serine/threonine metabolism 8/40 8.65E-08 6.55E-06 13.889 225.88
Proteoglycans in cancer 14/203 1.55E-06 9.38E-05 4.7893 64.07
Osteoclast differentiation 11/128 2.50E-06 1.26E-04 5.9679 76.98
Leukocyte transendothelial migration 10/115 6.46E-06 2.80E-04 6.0386 72.16
Hematopoietic cell lineage 9/94 8.57E-06 3.25E-04 6.6489 77.57
Lysosome 10/124 1.26E-05 4.25E-04 5.6004 63.17
Top ten enrichments are shown. Full details of all enrichments and genes are provided in Extended data: Table S3.
Figure 6. Principal component analysis comparing L. donovani infected, AmBisome®-treated L. donovani-infected and naïve mice 
BALB/c mice. A and B. Eigen values were generated using the normalised expression values for differentially expressed genes in spleen 
(A) and liver (B). PCA analysis was performed in R using the prcomp package and the percentage contribution each condition (treatment 
and infection status) has to the expression value/ eigenvalue used to summarise the data; and the directionality of the first two principle 
components is shown as a biplot. The percentage of the variability in the data explained by first two components is the sum of the percentages 
given on both the x and y axis.
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DOWN) at R
x
+7 (Extended data: Table S4). The overlap between 
these genes across organ and time post treatment is shown as a 
venn diagram generated using Venny 2.1 (Figure 741), illus-
trating the distinctive nature of the return to homeostasis in 
spleen and liver. Our previous analysis identified 3055 and 
2805 DE genes at d42 post infection in liver and spleen respec-
tively, when comparing d42 infected mice with control 
uninfected mice30. Of the genes DE in the liver between 
naïve and R
x
+7 mice, 97% (1476/1518) were represented in 
the original infection-associated gene list. Similarly, 91% 
(1085/1196) of DE genes in spleen identified in a comparison 
of R
x
+7 vs naïve mice were also found in the original infected 
vs naïve DE list. This suggests that most transcriptomic changes 
that remain after treatment with AmBisome® represent a sub-
set of those initially induced by infection. However, amongst 
the 74 immune-associated genes downregulated by AmBisome® 
treatment in the liver (Figure 2), only 9.45% (7/74) returned 
fully to homeostatic levels (H2-M2, H2-Eb2, Cxcl1, IL6, Lag 3, 
Tnfsf15 and Tnfrsf9 (CD137, 4–1BB), indicating a high 
level of residual immune activity in the liver despite the loss 
of discrete granulomas.
In order to further analyse DE genes that did not revert to home-
ostatic levels, we used gene set enrichment, employing the 
EnrichR tool. Analysis of the residual 1518 DE genes in the 
liver post treatment using Go Biological Processes, GO Molec-
ular Function, Mouse Gene Atlas and Wiki Pathways are 
provided in Extended data: Table S5. GO terms related to 
cytokine signalling, inflammation, T cell and neutrophil mediated 
immunity, were the most significant. Wiki Pathways identified 
chemokine signalling, microglia pathogen phagocytosis, 
IFNG signalling and TYROBP Causal Network WP4625 
(a microglial activation pathway), and the Mouse Atlas 
analysis revealed predominantly myeloid cell populations. 
Similar analysis for the residual 1196 DE genes in spleen 
(Extended data: Table S6) suggested a prominent role for 
neutrophils and endothelial cells in the post cure phase of 
experimental VL, including GO Molecular Function terms related 
to neutrophil mediated immunity, degranulation and activation 
and both neutrophil and endothelial cell chemotaxis. Similarly, 
GO Molecular Function terms for a variety of serine-type and 
metallopeptidases were highly ranked alongside multiple terms 
related to chemokine biology. 
Of note, the top upstream transcription factors predicted by 
IPA analysis to regulate spleen residual genes were Gata2 (94 
predicted targets; p=3.07x10-43; z score 1.707, predicting 
activation of the regulator), Mrtfb (Mkl2; 41 predicted targets; 
p=6.92x10-33; z score -5.204, predicting inhibition of the regula-
tor) and Mrtfa (Mkl1; 49 predicted targets; p=5.12x10-31; z score 
-4.232, predicting inhibition of the regulator). Gata2 is associ-
ated with haematopoiesis / stem cell function, whereas Mrtfb 
and Mrtfa are associated with tissue organization, abnormal 
morphology and tissue remodeling, as well as with throm-
bocytopenia (a hallmark of human and experimental VL42,43. 
Collectively, these data suggest that spleen is in a state of 
active “repair”.
AmBisome® treatment is reflected by a loss of a systemic 
gene signature associated with L. donovani infection in 
mice
Finally, we had previously identified a transcriptomic signature 
of 26 predominantly interferon regulated genes that was com-
monly upregulated by infection with L. donovani in spleen, 
liver and blood regardless of time post infection30. We therefore 
examined the impact of AmBisome® treatment on expression 
of this systemic disease-associated signature. In the liver 
(Figure 8A) and spleen (Figure 8B) of AmBisome®-treated mice, 
the entire signature gene set was downregulated compared to 
untreated mice, in a time dependent manner. However, a full 
restoration to the homeostatic mRNA abundance seen in 
uninfected control mice was only occasionally noted.
Discussion
VL is a systemic disease and understanding disease progression and 
the response to chemotherapy is dependent upon a more complete 
understanding of how target tissues respond over time. Although 
in recent years the evaluation of immune and other changes asso-
ciated with human disease progression and drug response has 
adopted a more systematic approach employing -omics tech-
nologies, the invasive nature of tissue sampling has largely 
restricted this approach to whole blood20,21,44,45. Here, we used 
the BALB/c model of VL to directly explore the breadth of tran-
scriptomic changes associated with AmBisome® treatment. 
Although there are undoubtedly differences between rodent 
models and humans, as we have recently highlighted30, it is 
worth recalling the instrumental role that the BALB/c mouse 
model played in supporting the clinical use of AmBisome®46,47. 
To study drug response, we chose to focus on a relatively late 
time (d35 post infection) for drug treatment when chronic 
pathology is established in the spleen, and used a dose of 
AmBisome® for which anti-parasitic efficacy has been shown 
previously in liver and spleen38,48. 
Figure 7. Venn diagram to illustrate overlap in DE genes between 
all treatment groups. Venn diagram representing all DE genes 
listed in Extended data: Table S4 in spleen and liver at each time 
point after AmBisome® treatment.
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Figure 8. Restoration of 26 gene signature in spleen and liver following AmBisome treatment in L. donovani infected BALB/c mice. 
Data is shown in heat map format for the 26 genes identified as a common transcriptional signature of infection in blood, spleen and liver of 
L. donovani infected mice30. Scale represents gene expression values, with no column wise or row wise normalisation applied. A and B. The 
dendrogram illustrates liver (A) and spleen (B) data clustered both by the similarity in the pattern of expression per gene (y axis), and by the 
similarity in gene expression between individuals (x axis).
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The hepatic response to AmBisome® treatment was as expected 
rapid, with hepatic parasite load reduced by >50% at R
x
+1 and 
to below detection levels by R
x
+7. At R
x
+1, there appeared no 
direct histopathological correlate of drug action, but by R
x
+7 
most granulomas had regressed, and those that remained had 
reduced cellularity. Transcriptomic analysis of hepatic tissues 
largely mirrored this histopathological evaluation. Less than 3% 
of genes DE during infection30 changed in their mRNA abun-
dance one day after treatment, reflecting the intact granulomatous 
response. At R
x
+7, when mice had fully cleared their infection to 
below detection limits, this rose to ~13% (400/3055) of the 
total infection-induced DE genes, coincident with a loss of 
granulomas from the tissue. Although pathway and enrich-
ment analysis identified some changes in inflammatory path-
ways, metalloprotease activity and some metabolic pathways, 
FDR values were modest at R
x
+7. Such analysis more 
robustly identified pathways associated with immune func-
tion, particularly within the “down regulated” genes, as might 
be expected from the dramatic loss of inflammatory granulo-
mas. Although by d42 post infection, spontaneous resolution of 
hepatic infection is already well under way, the reduction of 
parasite load due to AmBisome® treatment clearly accelerates 
this process. Hence, it is not possible to say whether specific cell 
populations involved in granuloma development and function 
specifically alter their gene expression profile following treat-
ment. Similarly, it is possible that small changes in parenchy-
mal cell responses after treatment may have been overlooked 
due to the high signal to noise for immune cells generated by 
altered states of inflammation. Further studies using spatially 
resolved and/or single cell analysis will be required to 
address this question. 
To specifically address whether AmBisome® treatment might 
impact directly on host response in the absence of any anti-
microbial activity we sought an alternate in vivo approach. 
Although AmBisome® treatment of naïve mice might appear 
an obvious experimental approach, we felt that this would not 
fully reflect the potential for drug action on cells already acti-
vated during inflammation and through antigen-specific immune 
responses, nor would it mimic the impact of infection-associated 
pathology on drug distribution38. We therefore elected to use 
an infection model with M. bovis BCG, which has previ-
ously been shown to induce both splenomegaly and granulo-
matous inflammation in the liver, not too dissimilar from that 
seen in experimental VL26,40. At a conventional threshold of 
2-fold change, only three genes were found to be DE seven 
days after AmBisome® treatment. Removal of this thresh-
old revealed that many of the immune changes observed in 
Leishmania-infected mice treated with AmBisome® had not 
occurred in BCG-infected drug treated mice, in keeping with 
maintenance of granuloma integrity. More strikingly, AmBisome® 
treatment of BCG-infected mice uncovered a number of signifi-
cant albeit small changes in mRNA abundance for genes associ-
ated with myeloid cell function. We conclude that by removing 
the confounding factor of anti-microbial activity, this has revealed 
for the first time the full breadth of this drug’s immunomodula-
tory potential within an in vivo inflammatory environment. 
These results may aid interpretation of the mode of action of 
AmBisome® in other settings, such as fungal disease. 
Splenomegaly in experimental VL is associated with compart-
ment specific remodelling of the red and white pulp, mediated 
through the action of TNF, inflammatory monocytes and loss of 
stromal cell integrity32,49–52. Analysis of the splenic response at 
R
x
+7 provided evidence for diminution of the cellular responses 
though not to the same extent as seen in the liver. Notably, 
examination of residual genes DE in treated vs. naïve mice 
indicated that these reflected a number of pathways associated 
with remodelling and stem cell activity. This is perhaps not sur-
prising given that these mice still exhibit splenomegaly and 
architectural disruption. Spleen structure is highly dynamic 
during infection, with the capacity for rapid resolution once 
infectious load has been cleared. For example, in the case of 
murine cytomegalovirus infection, spleen architecture and func-
tion is fully restored within days of the drop in tissue viral 
load, through mechanisms that involve the reactivation of 
RORG-dependent lymphoid tissue inducer cells53,54. In contrast, 
with L. donovani infection restoration of lymphoid tissue 
architecture by the receptor tyrosine kinase inhibitor sunitinib 
was observed to be independent of RORG32 and splenomegaly can 
persist even after highly effective elimination of parasite load. 
Transcriptomic analysis of the spleen response to L. donovani 
infection highlighted the complexity and dynamics of this 
process30, identifying key pathways with progressive evolu-
tion of a complex immune and metabolic environment. Our data 
indicate that much of this remains intact even after parasite 
clearance, with only some reduction in macrophage activation 
signatures. We cannot rule out, and it is indeed likely, that 
splenomegaly and a state of immune activation persists partly 
as a consequence of low-grade infection below the limits of 
detection by the smear technique used here. However, it is 
noteworthy that the presence of parasite and parasite-mediated 
immune responses are not in themselves the sole regulator of 
this process. For example, mice treated with sunitinib retain 
a full parasite load yet show restoration of splenic architec-
ture and partially regain immune competence32, indicating 
the independence of pathology and parasite load. 
In the clinic, splenomegaly is a common diagnostic charac-
teristic for VL. The extent of splenomegaly at presentation is 
a significant risk factor for treatment failure, as is the pres-
ence of splenomegaly at the end of standard of care. For exam-
ple, a study in southern Sudan indicated an odds ratio for 
relapse of 5.50 (1.84, 16.49) for patients discharged with a 
Hackett grade for splenomegaly q 329. Our data go some way 
to understanding the ongoing process of splenic remodel-
ling that may also therefore be occurring in human disease. 
Whether these would be accelerated, as in the mouse by the 
use of combination therapies targeting remodelling, such as 
sunitinib, remains to be seen. It would also be of interest to evalu-
ate the response of mice to AmBisome® treatment after longer 
periods of recovery.
Although not directly analysing the tissue response, others 
have examined the response to treatment at the transcriptional 
level. Gardinassi et al. reported on a whole blood transcrip-
tomic analysis comparing 8 patients admitted with L. infantum 
VL in Teresina, Brazil; 8 different patients in remission 
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following treatment for 2–5 months with antimonials; 12 DTH-
positive putative asymptomatics and 15 DTH-negative healthy 
endemic controls44. Despite limitations in study design, these 
data suggest that blood transcriptional profiles of patients 
in regression are distinct from both active cases and healthy 
controls. More recently, Fakiola et al. conducted a longitudinal 
study of the whole blood transcriptomic signature in L. donovani 
VL patients in Bihar, India, examining two independent cohorts 
(n=10 and 11) of patients before and after different regi-
mens of amphotericin B treatment (repeated non-liposomal 
amphotericin B and single dose AmBisome®)20. As noted here, 
the major pathways associated with treatment response were 
related to interferon signalling, immune response and myeloid 
cell function. More importantly in the context of the current 
discussion, PCA analysis clearly demonstrated that the whole 
blood transcriptome of treated and cured VL patients does not 
return to a homeostatic baseline, at least within the 30 day fol-
low up period. The extent to which these responses normalised 
also varied between treatment regimens, suggesting that blood 
transcriptomic signature may be a powerful tool for identifying 
biomarkers associated with treatment success20. Collectively, 
these data suggest that patients discharged after receiving 
treatment for VL are some way away from fully restoring 
normal immune and physiological functions. This may have 
significant implications for understanding the basis of VL 
relapse and progression to PKDL, as well as responses to 
secondary unrelated infections and / or vaccines. Further 
studies are in progress to address these issues in patients with 
VL in East Africa (https://www.prevpkdl.eu).
In conclusion, the results presented in this manuscript have 
identified the key transcriptional changes associated with 
AmBisome®-induced parasite clearance in the spleen and liver 
of BALB/c mice infected with L. donovani and the extent to 
which such parasitologically-cured mice still deviate from 
homeostasis. In addition, we have identified previously hidden 
in vivo responses associated with administration of AmBisome®. 
Together, these data provide the foundation for further studies 
on tissue level transcriptional responses to treatment in humans 
and a rich resource for scientists wishing to further explore 
the mode of action of AmBisome®.
Data availability
Underlying data
Tissue and host species specific transcriptional changes in 
models of experimental visceral leishmaniasis, Mus musculus, 
Microarray data, Ascension number GSE113376: https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE113376 
Tissue-specific transcriptomic changes associated with AmBi-
some treatment of mice with experimental visceral leishmaniasis 
[LV9], Mus musculus, Microarray data, Ascension number 
GSE140799: https://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE140799
Tissue-specific transcriptomic changes associated with AmBi-
some treatment of mice with experimental visceral leishmaniasis, 
Mus musculus, RNA-Seq data, Ascension number GSE138825: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE138825
Whole slide images and individual mouse metadata will be 
available from www.leishpathnet.org (study designations 
CRACKIT-1 and CRACKIT-2). Requests for access to tissue 
samples from these studies will be accommodated where possible 
and subject to availability.
Extended data
Open Science Framework: CRACKIT Virtual Infectious 
Diseases project, https://doi.org/10.17605/OSF.IO/9WSDK55. This 
version of the project registered on 22nd November 2019.
This project contains the following extended data:
-    Figure S1. STRING analysis of down regulated 
genes in liver after AmBisome® treatment at R
x
+7. 
GO terms related to host defense (red) immune system 
process (blue) and KEGG pathways cytokine-cytokine 
receptor pathways (green) and Leishmaniasis (yellow) are 
indicated.
-    Figure S2. STRING analysis of up regulated genes in 
liver after AmBisome® treatment at R
x
+7. GO terms 
related to fatty acid metabolism (red), monocarboxylic 
acid metabolic processes (blue) and lipid metabolic 
process (light green) and KEGG pathways insulin signal-
ling (dark green), biosynthesis of fatty acids (purple) and 
fatty acid elongation (yellow) are indicated.
-    Figure S3. STRING analysis of differentially 
expressed genes in liver after AmBisome® treatment of 
M. bovis BCG infected mice at R
x
+7. Reference pub-
lications related to lysosomal and innate immunity (red; 
9/17 genes; FDR 5.69x10-12;1), meningiomas (blue; 
19/93 genes; FDR 3.92x10-11;2) CNS inflammation acti-
vation (light green; 14/39 genes; FDR 3.10x10-10;3), 
lupus (yellow; 17/78 genes; FDR 3.10x10-10;4) and 
atherogenesis (purple; 17/78 genes; FDR 3.10x10-10;5) are 
indicated in footnotea
a
 1. Alam MS, Getz M, Safeukui I, Yi S, Tamez P, Shin J, et al. Genomic 
expression analyses reveal lysosomal, innate immunity proteins, as disease 
correlates in murine models of a lysosomal storage disorder. PloS one. 
2012;7(10):e48273. Epub 2012/10/25. doi: 10.1371/journal.pone.0048273. 
PubMed PMID: 23094108; PubMed Central PMCID: PMCPMC3477142.
2. Domingues PH, Teodosio C, Otero A, Sousa P, Ortiz J, Macias Mdel C, 
et al. Association between inflammatory infiltrates and isolated monosomy 
22/del(22q) in meningiomas. PloS one. 2013;8(10):e74798. Epub 
2013/10/08. doi: 10.1371/journal.pone.0074798. PubMed PMID: 24098347; 
PubMed Central PMCID: PMCPMC3788099.
3. Bonasera SJ, Arikkath J, Boska MD, Chaudoin TR, DeKorver NW, 
Goulding EH, et al. Age-related changes in cerebellar and hypothalamic 
function accompany non-microglial immune gene expression, altered syn-
apse organization, and excitatory amino acid neurotransmission deficits. 
Aging (Albany NY). 2016;8(9):2153-81. Epub 2016/10/01. doi: 10.18632/
aging.101040. PubMed PMID: 27689748; PubMed Central PMCID: 
PMCPMC5076456.
4. Berthier CC, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, 
Zhang W, et al. Cross-species transcriptional network analysis defines shared 
inflammatory responses in murine and human lupus nephritis. J Immunol. 
2012;189(2):988-1001. Epub 2012/06/23. doi: 10.4049/jimmunol.1103031. 
PubMed PMID: 22723521; PubMed Central PMCID: PMCPMC3392438.
5. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics 
during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31(7):1506-16. 
Epub 2011/06/17. doi: 10.1161/ATVBAHA.110.221127. PubMed PMID: 
21677293; PubMed Central PMCID: PMCPMC3133596. ·½»ʸʻÅ¼ʹʸ
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-    Table S1. DE genes following AmBisome® treat-
ment in spleen and liver of L. donovani infected 
BALB/c mice. Each tab shows genes lists for each time 
point and each organ, with log2FC.
-    Table S2. GSEA analysis for liver and spleen DE 
genes in L. donovani infected mice at both times post 
AmBisome® treatment. Relates to Figure 3. Note: no 
significant enrichments were found for spleen at d36.
-    Table S3. DE gene identified in the liver of AmBisome® 
treated BALB/c mice infected with M. bovis BCG.
DE list contains all genes passing p value cut off of 0.05 
with no FC threshold.
-    Table S4. DE genes in spleen and liver of L. donovani 
infected mice, comparing AmBisome® treated mice to 
naïve mice.
-    Table S5. Pathway analysis of residual DE genes in liver 
of AmBisome® treated mice L. donovani infected mice, 
compared to naïve mice. Enrichments are shown for the 
following: GO Biological Processes, Molecular Function, 
Mouse Gene Atlas and WikiPathways2019Mouse.
-    Table S6. Pathway analysis of residual DE genes in spleen 
of AmBisome® treated mice L. donovani infected mice, 
compared to naïve mice. Enrichments are shown for the 
following: GO Biological Processes, Molecular Function, 
Mouse Gene Atlas and WikiPathways2019Mouse.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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